
Ask a doctor about a prescription for SUMATRIPTAN VIATRIS 50 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Sumatriptan Viatris 50 mg Film-Coated Tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.Keep this leaflet. You may need to read it again.
Contents of the pack
This medicine contains the active substance sumatriptan succinate. Sumatriptan succinate belongs to a group of medicines called 5-HT1 receptor agonists, which are used to treat migraine attacks. Migraine usually causes headaches, sometimes with vomiting, or other symptoms such as, for example, sensitivity to light or sound in some people. The symptoms of migraine can be caused by temporary dilation of blood vessels in the brain. It is believed that sumatriptan reduces the dilation of these blood vessels.
Sumatriptan should not be used if you have not been diagnosed with migraine and does not prevent a migraine attack.
Do not take Sumatriptan Viatris:
Warnings and precautions
Sumatriptan should not be used for rare forms of migraine caused by brain or eye problems (e.g., hemiplegic migraine, basilar migraine, or ophthalmoplegic migraine).
Consult your doctor or pharmacist before starting to take Sumatriptan Viatris:
If you take Sumatriptan Viatris regularly
Taking sumatriptan too frequently can cause or worsen headaches. This can also happen if you need to use other medicines, such as painkillers, regularly for migraine. Talk to your doctor or pharmacist if this happens to you.
Sumatriptan Viatris may cause chest and throat tightness
You may notice pain or tightness in the chest and throat after taking sumatriptan. If these symptoms do not go away soon, contact your doctor immediately.
Other medicines and Sumatriptan Viatris
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. In particular, you should tell your doctor if you are taking:
If you are taking or have taken other medicines for migraine
If you have taken other medicines for migraine, such as ergotamine or ergotamine derivatives (such as methysergide), or a triptan/5-HT1 agonist (such as naratriptan or zolmitriptan), you should wait at least 24 hours before taking sumatriptan.
If you have taken sumatriptan, you should wait at least 6 hours before taking ergotamine or derivatives (such as methysergide) and at least 24 hours before taking a triptan/5-HT1 agonist.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Only limited information is available on the safety of sumatriptan for pregnant women, although so far there is no evidence that it increases the risk of congenital malformations. Your doctor will discuss with you whether you should use sumatriptan during pregnancy.
If you are breastfeeding, you should be aware that sumatriptan is excreted in breast milk. Suspend breastfeeding for the 12 hours following administration of sumatriptan. Breast milk should be expressed and discarded during this time.
Driving and using machines
This medicine, like migraine, can cause drowsiness, dizziness, or nausea. If this happens, it may affect your ability to drive or operate machinery. Caution is recommended if you perform such activities.
Sumatriptan Viatris contains lactose and sodium
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
Adults
The recommended dose is one 50 mg tablet. In some cases, a dose of 25 mg or 100 mg may be necessary. Since the tablet cannot be divided into two equal doses, if necessary, your doctor should prescribe another medicine with the same active substance, dose, and pharmaceutical form available in a divisible tablet.
If you experience some improvement but the headache comes back, you can take a second dose within 24 hours, provided that there is a minimum interval of 2 hours between the two doses. The maximum dose is 300 mg of sumatriptan every 24 hours. Swallow the tablet whole with the help of a glass of water.
Do not take a second dose if the first dose has no effect. If sumatriptan has no effect after the first dose, you can take instead a painkiller such as paracetamol, a non-steroidal anti-inflammatory drug (NSAID), for example, aspirin (acetylsalicylic acid) or ibuprofen.
Use in children and adolescents (under 18 years)
Sumatriptan is not recommended for use in children and adolescents.
Use in elderly patients (over 65 years)
Sumatriptan is not recommended for use in elderly patients.
Patient with liver problems
If you have mild or moderate liver problems, your doctor may recommend that you take a lower dose.
If you take more Sumatriptan Viatris than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service (telephone 91 562 04 20), indicating the medicine and the amount taken. It is recommended to take the package and the leaflet of the medicine to the healthcare professional.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some of the side effects observed may be side effects associated with migraine.
If you experience any of the following side effects, stop taking this medicine immediately and seek urgent medical advice:
Frequency not known (cannot be estimated from the available data)
Other side effects:
Frequent (may affect up to 1 in 10 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicine does not require any special storage conditions.
Do not use this medicine after the expiry date which is stated on the carton or blister after EXP. The expiry date refers to the last day of that month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Sumatriptan Viatris
The active substance is sumatriptan (as succinate). Each film-coated tablet contains 50 mg of sumatriptan (as succinate).
The other ingredients are: lactose monohydrate, microcrystalline cellulose, sodium croscarmellose, and magnesium stearate. The coating contains titanium dioxide (E-171), polydextrose (E-1200), hypromellose (E-454), triacetin (E-1518), macrogol, red iron oxide (E-172), and yellow iron oxide (E-172). (See section 2 "Sumatriptan contains lactose and sodium").
Appearance of the product and pack contents
Round, pink tablets, engraved on one side with "SU50" and "G" on the other.
Sumatriptan Viatris is available in blisters of 2, 3, 4, 5, 6, 10, 12, 18, 20, and 24 tablets or in single-dose blisters of 4 tablets.
Not all pack sizes may be marketed.
The blister may contain empty triangular pockets that do not contain tablets. Only the round pockets of the blister contain tablets.
Marketing authorization holder:
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer
McDermott Laboratories Ltd. t/a Gerard Laboratories
35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13
Ireland
or
Mylan Hungary Kft.
Mylan útca. 1
Komárom
2900
Hungary
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Spain: Sumatriptan Viatris 50 mg film-coated tablets EFG
Italy: Sumatriptan Mylan 50 mg film-coated tablets
United Kingdom (Northern Ireland): Sumatriptan 50 mg film-coated tablets
Date of last revision of this leaflet:February 2025
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/
The average price of SUMATRIPTAN VIATRIS 50 mg FILM-COATED TABLETS in November, 2025 is around 12.18 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for SUMATRIPTAN VIATRIS 50 mg FILM-COATED TABLETS – subject to medical assessment and local rules.